



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

	Application Number	10/723,955	
	Filing Date	November 26, 2003	
	First Named Inventor	Dominic P. Behan	
	Art Unit	Not Yet Assigned	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	26	Attorney Docket Number	7.US29.CON

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):		
<table><tr><td>Remarks</td><td></td></tr></table>			Remarks	
Remarks				

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David A. Sadewasser/Reg. No. 55,587
Signature	<i>David Sadewasser</i>
Date	<i>February 18, 2004</i>

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	David A. Sadewasser		
Signature	<i>David Sadewasser</i>	Date	<i>February 18, 2004</i>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Dominic P. Behan, et al

Serial No.: 10/723,955


Group Art Unit: Not Yet Assigned

Filing Date: November 26, 2003

Examiner: Not Yet Assigned

For: CONSTITUTIVELY ACTIVATED
HUMAN G PROTEIN COUPLED RECEPTORS

DATE OF DEPOSIT: February 18, 2004
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450


TYPED NAME: David A. Sadewasser
REGISTRATION NO: 55,587

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).
- ☐ Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

- ☐ In view of the voluminous nature of reference @@@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☒ Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 10/417,820 filed on April 16, 2003.
- ☒ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
- ☐ The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$_____. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.

☒ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



David A. Sadewasser
Registration No. 55,587

Dated: February 18, 2004

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/723,955
				Filing Date	November 26, 2003
				First Named Inventor	Dominic Behan
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	7.US29.CON
Sheet	18	of	21		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 19 of 21

Complete if Known

Application Number	10/723,955
Filing Date	November 26, 2003
First Named Inventor	Dominic Behan
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	7.US29.CON

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	JJ	MOORE, et al., "The role of cAMP regulation in controlling inflammation," Clin. Exp. Immunol. (1995) 101:387-389.	
	JK	IM, et al., "Identification of a molecular target of psychosine and its role in globoid cell formation," J. Cell Biol. (2001) 153:429-434.	
	JL	TOSA, et al., "Critical function of t cell death-associated gene 8 in glucocorticoid-induced thymocyte apoptosis," Intl. Immunol. (2003) 15:741-749	
	JM	CHOI, et al., "Identification of a putative G protein-coupled receptor induced during activation-induced apoptosis of T cells," Cell. Immunol. (1996) 168:78-84.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

20

of

21

Complete if Known

Application Number

10/723,955

Filing Date

November 26, 2003

First Named Inventor

Dominic Behan

Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

7.US29.CON

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	JN	US-6,455,685	09/24/2002	Levinson	
	JO	US- 6,414,117	07/02/2002	Levinson	
	JP	US- 6,204,371	03/20/2001	Levinson	
	JQ	US- 2002/0106741 A1	08/08/2002	Li et al	
	JR	US- 6,436,703	08/20/2002	Teng et al	
	JS	US- 2002/0061567 A1	05/23/2002	Teng et al	
	JT	US- 6,288,218	09/11/2001	Levinson	
	JU	US- 2002/0146757 A1	10/10/2002	Teng et al	
	JV	US- 6,156,887	12/05/2000	Levinson	
	JW	US- 6,084,083	07/04/2000	Levinson	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	JX	WO02/57414	07/25/02	Bio-Cardia		
	JY	WO02/61087	08/08/02	Lifespan Biosciences		
	JZ	WO00/73498	12/07/00	Millenium Pharm.		
	KA	WO96/27603	09/12/96	Millenium Pharm.		
	KB	WO00/22131	04/20/00	Behan et al		
	KC	WO96/32858	07/30/96	Schering Corp.		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

21

of

21

Complete if Known

Application Number

10/723 955

Filing Date

November 26, 2003

First Named Inventor

Dominic Behan

Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

7.US29.CON

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	KD	WO00/21991	04/20/00	Genetics Institute		
	KE	WO01/75067	10/11/01	Hyseq		
	KF	WO96/39442	12/12/96	Human Genome Sciences		
	KG	WO02/77153	10/03/02	U. Virginia		
	KH	WO02/10449	02/07/02	Compugen		
	KI	WO01/75067	10/11/01	Hyseq		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



Sheet 1 of 21

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7.US29:CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Alla, S.A. et al., "Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies," <i>J. Biol. Chem.</i> , 1996, 271, 1748-1755
AB	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK ₂) receptors," <i>Am. Rev. Respir. Dis.</i> , 1992, 146(5, Pt. 1), 1177-1181
AC	Alexander, W.S. et al., "Point mutations within the dimer interact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , 1995, 14(22), 5569-5578
AD	Arvanitakis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , 1997, 385, 347-349
AE	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine _{2c} receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , 1994, 269(16), 11687-11690
AF	Baxter, G., "5-HT ₂ receptors: a family re-united?" <i>Trends Pharmacol. Sci.</i> , 1995, 16, 105-110
AG	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene v- <i>kit</i> with the protein kinase gene family," <i>Nature</i> , 1986, 320, 415-421
AH	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G _{q11} by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , 1995, 270, 17741-17748
AI	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, 1998, 363-377
AJ	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(21), 9921-9925

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7.US29.CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**AK**

Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," *Biochem. Pharmacol.*, 1996, 51(4), 539-544

AL

Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," *J. Biol. Chem.*, 1996, 271(6), 2882-2885

AM

Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein G_q ," *FEBS Lett.*, 1995, 363(3), 261-263

AN

Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," *Pharmacol. Rev.*, 1994, 46, 121-136

AO

Casey, C. et al., "Constitutively active mutant 5-HT_{2A} serotonin receptors: inverse agonist activity of classical 5HT_{2A} antagonists," *Soc. Neurosci.*, 1996, Abstract #699.10

AP

Cheatham, B. et al., "Substitution of the *erbB-2* oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," *Proc. Natl. Acad. Sci. USA*, 1993, 90, 7336-7340

AQ

Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," *J. Biol. Chem.*, 1995, 270, 23398-23401

AR

Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," *J. Antibiot. (Tokyo)*, 1993, 46(1), 131-134

AS

Chen, W. et al., "A colorimetric assay for measuring activation of G_i - and G_q -coupled signaling pathways," *Anal. Biochem.*, 1995, 226(2), 349-354

AT

Chidiac, P. et al., "Inverse agonist activity of β -adrenergic antagonists," *J. Pharm. Exp. Ther.*, 1994, 45, 490-499

AU

Clozel, M. et al., "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," *J. Cardiovas. Pharmacol.*, 1993, 22(Suppl. 8), S377-S379

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified**Docket No.**

7.US29.CON

Serial No.

10/723,955

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AV	Collesi, C. et al., "A splicing variant of the <i>RON</i> transcript induces constitutive tyrosine kinase activity and an invasive phenotype," <i>Mol. Cell. Biol.</i> , 1996, 16(2), 5518-5526
AW	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , 1984, 311, 29-33
AX	De Dios, I. et al., "Effect of L-364,718 (CCK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats," <i>Pancreas</i> , 1994, 9(2), 212-218
AY	Desbios-Mouthon, C. et al., "Deletion of Asn ²⁸¹ in the α -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , 1996, 81(2), 719-727
AZ	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , 1991, 6(11), 1997-2003
BA	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," <i>Oncogene</i> , 1992, 7, 2549-2553
BB	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism," <i>Nature Genetics</i> , 1994, 7, 396-401
BC	Eggericksx, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , 1995, 309, 837-843
BD	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," <i>J. Med. Chem.</i> , 1992, 35, 3919-3927
BE	Fu, M. et al., "Functional autoimmune epitope on α_1 -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , 1994, 344, 1660-1663
BF	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto-oncogene <i>c-kit</i> in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of <i>c-kit</i> Product," <i>J. Clin. Invest.</i> , 1993, 92, 1736-1744
BG	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), 200-206

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified**Docket No.**

7.US29.COM

Serial No.

10/723,955

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BH	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , 1995, 275(2), 737-744
BI	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , 1996, 87(5), 1692-1697
BJ	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , 1995, 11(1), 76-82
BK	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," <i>J. Biol. Chem.</i> , 1996, 271(4), 1857-1860
BL	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," <i>J. Clin. Invest.</i> , 1984, 74, 647-651
BM	Herrick-Davis, K. et al., "Constitutively Active 5HT _{2C} Serotonin Receptor Created by Site-Directed Mutagenesis," <i>Soc. Neurosci.</i> , Abstract No. 699.18
BN	Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , 1995, 47, 267-270
BO	Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," <i>Am. Soc. Pharm. Exp. Therap.</i> , 1990, 42(1), 45-83
BP	Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," <i>J. Biol. Chem.</i> , 1995, 270(13), 7405-7410
BQ	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene <i>c-kit</i> in Acute Myeloblastic Leukemia Cells," <i>Blood</i> , 1991, 78(11), 2962-2968
BR	Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," <i>Mol. Pharm.</i> , 1992, 42, 982-990

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7.US29.CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**BS**

Jakubik, J. et al., "Constitutive activity of the M₁-M₄ subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," *FEBS Letts.*, 1995, 377, 275-279

BT

Kjelsberg, M.A. et al., "Constitutive activation of the α_{1B} -adrenergic receptor by all amino acid substitutions at a single site," *J. Biol. Chem.*, 1992, 267(3), 1430-1433

BU

Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," *FASEB J.*, 1995, 9, 516-525

BV

Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," *Human Mol. Genetics*, 1995, 4(2), 183-188

BW

Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," *Mol. Endocrinology*, 1993, 7, 114-130

BX

Kraus, M. et al., "Demonstration of ligand-dependent signaling by the *erbB-3* tyrosine kinase and its constitutive activation in human breast tumor cells," *Proc. Natl. Acad. Sci. USA*, 1993, 90, 2900-2904

BY

Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," *J. Pharm. Exp. Therap.*, 1996, 277(2), 840-851

BZ

Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene *c-kit* Product," *Blood*, 1991, 78(11), 2834-2840

CA

Labbe-Jullie, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," *J. Pharm. Exp. Therap.*, 1994, 271(1), 267-276

CB

Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," *J. Clin. Endocrinol. Metab.*, 1995, 80(8), 2490-2494

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7.US29.CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**CC**

Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," *Proc. Natl. Acad. Sci USA*, 1995, 92, 1906-1910

CD

Løvlie, R. et al., "The Ca²⁺-sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," *Hum. Genet*, 1996, 98, 129-133

CE

Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," *Trends Pharmacol. Sci.*, 1993, 14, 303-307

CF

Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," *Nature*, 1985, 313, 144-147

CG

Liu, C. et al., "Overexpression of *c-met* proto-oncogene but not epidermal growth factor receptor or *c-erbB-2* in primary human colorectal carcinomas," *Oncogene*, 1992, 7, 181-185

CH

Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," *J. Biol. Chem.*, 1996, 271(11), 6172-6178

CI

Lonardo, F. et al., "The normal *erbB-2* product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," *New Biologist*, 1990, 2(11), 992-1003

CJ

Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," *Biochem. Biophys. Res. Comm.*, 1990, 173(3), 1169-1178

CK

Mann, J. et al., "Increased serotonin, and β -adrenergic receptor binding in the frontal cortices of suicide victims," *Arch. Gen. Psychiatry*, 1986, 43, 954-959

CL

Martone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8

CM

Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," *Circulation*, 1994, 89, 2760-2767

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7. US29 .CON.

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CN	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , 1995, 270(3), 1041-1047
CO	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , 1994, 14(7), 4843-4854
CP	Nanevich, T. et al., "Thrombin receptor activating mutations," <i>J. Biol. Chem.</i> , 1996, 271(2), 702-706
CQ	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , 1993, 68, 746-749
CR	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," <i>J. Biol. Chem.</i> , 1995, 270(44), 26037-26040
CS	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," <i>J. Pharm. Exp. Ther.</i> , 1992, 263(1), 241-245
CT	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β_2 -adrenergic receptor," <i>J. Biol. Chem.</i> , 1988, 263(31), 15985-15992
CU	Offermanns, S. et al., " $G_{\alpha_{15}}$ and $G_{\alpha_{16}}$ Couple a Wide Variety of Receptors to Phospholipase C," <i>J. Biol. Chem.</i> , 1995, 270, 15175-15180
CV	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," <i>J. Med. Chem.</i> , 1994, 37, 4508-4521
CW	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," <i>J. Biol. Chem.</i> , 1996, 271(14), 7949-7955
CX	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," <i>J. Clin. Endocr. Metab.</i> , 1996, 81, 3584-3588

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7. US29. CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , 1993, 365, 649-651
CZ	Pei, G. et al., "A constitutive active mutant β_2 -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 2699-2702
DA	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 265(3), 1348-1354
DB	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," <i>CNS Drugs</i> , 1995, 4 (Suppl. 1), 18-27
DC	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , 1993, 45, 289-293
DD	Prat, M.P. et al., "The receptor encoded by the human <i>c-Met</i> oncogene is expressed in hepatocytes, epithelial cells and solid tumors," <i>Int. J. Cancer</i> , 1991, 49, 323-328
DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , 1996, 49, 422-429
DF	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and ^3H -acetylcholine release from guinea-pig gallbladder," <i>Neuropeptides</i> , 1993, 25(5), 271-276
DG	Ren, Q. et al., "Constitutive active mutants of the α_2 -adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268, 16483-16487
DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active ET_A receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273(3), 1410-1417
DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , 1993, 72, 827-834
DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," <i>Cancer</i> , 1993, 53(22), 5355-5360

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified**Docket No.**

7.US29.CON

Serial No.

10/723,955

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**DK**

Samama, P. et al., "A mutation-induced activation state of the β 2-adrenergic receptor," *J. Biol. Chem.*, 1993, 268(7), 4625-4636

DL

Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," *Am. Soc. Pharm. Exp. Ther.*, 1996, 50, 285-292

DM

Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," *Can. J. Physiol. Pharmacol.*, 1995, 73, 805-811

DN

Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," *J. Rec. Signal Transduct. Res.*, 1997, 17(1-3), 57-73

DO

Scheer, A. et al., "The activation process of the α_{1B} -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," *Proc. Natl. Acad. Sci. USA*, 1997, 94, 808-813

DP

Schwinn, D.A. et al., "Cloning and pharmacological characterization of human α -1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," *J. Pharmacol.*, 1995, 272(1), 134-142

DQ

Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the *Xenopus laevis* oocyte expression system," *Proc. Natl. Acad. Sci. USA*, 1995, 92, 5699-5703

DR

Seeman, P. et al., "Dopamine receptor pharmacology," *Trends Pharmacol. Sci.*, 1994, 15, 264-270

DS

Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," *Nature*, 1993, 365, 441-445

DT

Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V_{1a} receptors," *J. Clin. Invest.*, 1993, 92, 224-231

DU

Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," *Mol. Cell. Endocrinology*, 1994, 100, 115-119

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7.US291.CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**DV**

Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," *Blood*, 1992, 80(12), 3070-3078

DW

Skinner, R.H. et al., "Direct measurement of the binding of RAS to neurofibromin using scintillation proximity assay," *Anal. Biochem.*, 1994, 223, 259-265

DX

Slamon, D.J. et al., "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/*neu* oncogene," *Science*, 1987, 235, 177-181

DY

Slamon, D. et al., "Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer," *Science*, 1989, 244, 707-712

DZ

Salomon, Y. et al., "A highly sensitive adenylate cyclase assay," *Anal. Biochem.*, 1974, 58, 541-548

EA

Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," *Ann. Rev. Physiol.*, 1995, 58, 143-170

EB

ter Laak, A. et al., "Modelling and mutation studies on the histamine H₁-receptor agonist binding site reveal different binding modes for H₁-agonists: Asp¹¹⁶ (TM3) has a constitutive role in receptor stimulation," *J. Computer-Aided Mol. Design*, 1995, 9, 319-330

EC

Tiberi, M. et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype," *J. Biol. Chem.*, 1994, 269(45), 27925-27931

ED

Tsujimura, T. et al., "Constitutive activation of *c-kit* in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain," *Blood*, 1996, 87(1), 273-283

EE

Wang, Z. et al., "Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence," *Life Sci.*, 1994, 54(20), 339-350

EF

Watowich, S.S. et al., "Homodimerization and constitutive activation of the erythropoietin receptor," *Proc. Natl. Acad. Sci USA*, 1992, 89, 2140-2144

EXAMINER**DATE CONSIDERED**

Form PTO-1449 ModifiedDocket No.
7. US29. CONSerial No.
10/723,955List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
Dominic P. Behan et al.U.S. Department of Commerce
Patent and Trademark OfficeFiling Date
November 26, 2003Group
Not Yet Assigned**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EG	Weber-Nordt, R.M. et al., "Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines," <i>Blood</i> , 1996, 88(3), 809-816
EH	Webster, M.K. et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane point mutation found in achondroplasia," <i>EMBO J.</i> , 1996, 15, 520-527
EI	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81, 7308-7312
EJ	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinas <i>in vitro</i> ," <i>J. Biol. Chem.</i> , 1992, 267(18), 12452-12461
EK	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Opioid Receptor-Like Orphan Receptor," <i>J. Biol. Chem.</i> , 1995, 270, 22772-22776
EL	Zhen, Z. et al., "Structural and functional domains critical for constitutive activation of the HGF-receptor (<i>Met</i>)," <i>Oncogene</i> , 1994, 9, 1691-1697
EM	Gantz, I. et al., "Molecular Cloning of a Novel Melanocortin Receptor," <i>J. Biol. Chem.</i> , 1993, 268(11), 8246-8250
EN	Heiber, M. et al., "Isolation of Three Novel Human Genes Encoding G Protein-Coupled Receptors," <i>DNA and Cell Biology</i> , 1995, 14(1), 25-35
EO	Howard, A.D. et al., "A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release," <i>Science</i> , 1996, 273, 974-977
EP	Iismaa, T.P. et al., "Isolation and Chromosomal Localization of a Novel Human G-Protein-Coupled Receptor (GPR3) Expressed Predominantly in the Central Nervous System," <i>Genomics</i> , 1994, 24, 391-394
EQ	Itoh, H. et al., "Molecular cloning and sequence determination of cDNAs for α subunits of the guanine nucleotide-binding proteins G_{α} , G_{β} , and G_{γ} from rat brain," <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 83, 3776-3780
ER	Jensen et al., "mRNA Profiling of Rat Islet Tumors Reveals Nkx 6.1 as a β -Cell-specific Homeodomain Transcription Factor," <i>J. Biol. Chem.</i> , 1996, 271(31), 18749-18758

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7. US29. CON.

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ES	Kenakin, T., "Are Receptors Promiscuous? Intrinsic Efficacy as a Transduction Phenomenon," <i>Life Sciences</i> , 1988, 43, 1095-1101
ET	Konig et al., "Method for Identifying Ligands That Bind to Cloned G _s - or G _i -Coupled Receptors," <i>Mol. Cell. Neuro.</i> , 1991, 2, 331-337
EU	Leonard, J. et al., "The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89, 6247-6251
EV	Marchese, A. et al., "Cloning of Human Genes Encoding Novel G Protein-Coupled Receptors," <i>Genomics</i> , 1994, 23, 609-618
EW	Marks, D.L. et al., "Simultaneous Visualization of Two Cellular mRNA Species in Individual Neurons by Use of a New Double <i>in Situ</i> Hybridization Method," <i>Mol. & Cell. Neuro.</i> , 1992, 3, 395-405
EX	O'Dowd, B. et al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes," <i>Gene</i> , 1997, 187, 75-81
EY	Sakurai T. et al., "Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior," <i>Cell</i> , 1998, 92, 573-585
EZ	Song, Z.-H. et al., "Molecular Cloning and Chromosomal Localization of Human Genes Encoding Three Closely Related G Protein-Coupled Receptors," <i>Genomics</i> , 1995, 28, 347-349
FA	Suzuki, M. et al., "Regulatable Promoters for Use in Gene Therapy Applications: Modification of the 5'-Flanking Region of the CFTR Gene with Multiple cAMP Response Elements to Support Basal, Low-Level Gene Expression that can be Upregulated by Exogenous Agents that Raise Intracellular Levels of cAMP," <i>Human Gene Therapy</i> , 1996, 7, 1883-1893
FB	Xu, Y. et al., "Identification of Human OGR1, a Novel G Protein-Coupled Receptor That Maps to Chromosome 14," <i>Genomics</i> , 1996, 35, 397-402
* FC	Nichols, J.G. et al. (eds.), "Indirect Mechanisms of Synaptic Transmission," in <i>From Neuron To Brain</i> , 3rd Edition, Sinauer Associates, Inc., 1992
* FD	Oslo et al. (eds.), in <i>Remington's Pharmaceutical Sciences</i> , 16th Edition, Mack Publishing Co., 1980

EXAMINER**DATE CONSIDERED**

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.

7:US29:CON

Serial No.

10/723,955

Applicant

Dominic P. Behan et al.

Filing Date

November 26, 2003

Group

Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	FE	5,514,578	05/07/96	Hogness et al.	435	240.2
	FF	5,532,157	07/02/96	Fink	435	240.2
	FG	5,573,944	11/12/96	Kirschner et al.	435	252.3
	FH	5,639,616	06/17/97	Liao et al.	435	7.1
	FI	5,750,353	05/12/98	Kopin et al.	435	7.21
**	FJ	09/170,496	10/13/98	Liaw et al.		
**	FK	09/364,425	07/30/99	Behan et al.		
**	FL	09/417,044	10/12/99	Chen et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	FM	WO 97/11159	09/20/96	PCT	X	

EXAMINER**DATE CONSIDERED**

**Pursuant to 37 C.F.R. 1.98(a)(2)(iii) no copy of a U.S. patent application need be included with an Information Disclosure Statement filed under 37 C.F.R. 1.97.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. 7. US29,300,000	Serial No. 10/723,955
	Applicant Behan et al.	
	Filing Date November 26, 2003	Group Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	GA	2,135,253	08.05.96	Canada	X	
EXAMINER				DATE CONSIDERED		

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. 7, US29, CON	Serial No. 10/723,955,
	Applicant Behan et al.	
	Filing Date November 26, 2003	Group Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	HA	WO 97 21731	19.06.97	PCT	X	
	HB	WO 98 38217	03.09.98	PCT	X	
	HC	WO 99 24569	20.05.99	PCT	X	
EXAMINER				DATE CONSIDERED		

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 7, US29, 2003	Serial No. 10/723,955
		Applicant Behan et al.	
		Filing Date November 26, 2003	Group Not yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	IA	Pauwels, et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors", <i>Molecular Biology</i> , 1998, 17, pp. 109-135.	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. 7. US29. CON	Serial No. 10/723,955
		Applicant Behan, et al.	
		Filing Date November 26, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	JA	Bergsma, D.J., et al., "Cloning and characterization of a human angiotensin II type 1 receptor," <i>Biochem. & Biophys. Res. Comm.</i> , 1992, XP-002145165, 183(3), 989-995	
	JB	Gantz, I., et al., "Molecular cloning, expression, and gene localization of a fourth melanocortin receptor," <i>J. Biol. Chem.</i> , 1993, XP-002051983, 268(20), 15174-15178	
	JC	Grobowski, T., et al., "Mutation of Asn ¹¹¹ in the third transmembrane domain of the AT _{1a} angiotensin II receptor induces its constitutive activation," <i>J. Biol. Chem.</i> , 1997, XP-002145162, 272(3), 1822-1826	
	JD	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophys. Res. Comm.</i> , 1994, XP-002145166, 203(3), 1842-1850	
	JE	Kyaw, H., et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene," <i>DNA and Cell Biology</i> , 1998, XP000929737, 17(6), 493-500	
	JF	Noda, K., et al., "The active state of the AT ₁ angiotensin receptor is generated by angiotensin II induction," <i>Biochem.</i> , 1996, XP-002145163, 35, 16435-16442	
	JG	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , 1996, XP-002145161, 219-2254	
	JH	Scheer, A., et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Receptor & Signal Transduction Res.</i> , 1997, XP-000867531, 17(1-3), 57-73	
EXAMINER		DATE CONSIDERED	